Register Login
Register to leave comments
  • News bot Oct. 24, 2025, 11:26 a.m.

    📋 KURA ONCOLOGY, INC. (KURA) - Clinical Trial Update

    Filing Date: 2025-10-24

    Accepted: 2025-10-24 07:24:52

    Event Type: Clinical Trial Update

    Event Details:

    Kura Oncology Inc (KURA) Announces Clinical Trial Update Kura Oncology Inc (KURA) provided an update on its clinical development programs. Clinical Development Highlights:
    • Collaboration: Common Stock
    • Updated Timeline: 2025-10-24 2025-10-24, October 24, 2025

    🔬 Clinical Development Pipeline (KURA ONCOLOGY, INC.):

    Product Type Development Stage Therapeutic Area Source
    Ziftomenib DRUG Phase PHASE3 Acute Myeloid Leukemia (AML) ClinicalTrials.gov
    Cytarabine (Ara-C) DRUG Phase PHASE3 Acute Myeloid Leukemia (AML) ClinicalTrials.gov
    Daunorubicin DRUG Phase PHASE3 Acute Myeloid Leukemia (AML) ClinicalTrials.gov
    Azacitidine (AZA) DRUG Phase PHASE3 Acute Myeloid Leukemia (AML) ClinicalTrials.gov
    Venetoclax DRUG Phase PHASE3 Acute Myeloid Leukemia (AML) ClinicalTrials.gov
    Placebo DRUG Phase PHASE3 Acute Myeloid Leukemia (AML) ClinicalTrials.gov
    Fludarabine DRUG Phase PHASE1 Relapsed/Refractory KMT2A-r Acute Leukemia ClinicalTrials.gov
    Cytarabine DRUG Phase PHASE1 Relapsed/Refractory KMT2A-r Acute Leukemia ClinicalTrials.gov
    Adagrasib DRUG Phase PHASE1 Solid Tumors With HRAS Alterations ClinicalTrials.gov
    Cabozantinib DRUG Phase PHASE1 Solid Tumors With HRAS Alterations ClinicalTrials.gov
    Darlifarnib DRUG Phase PHASE1 Solid Tumors With HRAS Alterations ClinicalTrials.gov
    Quizartinib DRUG Phase PHASE1 Acute Myeloid Leukemia ClinicalTrials.gov
    Azacitidine DRUG Phase PHASE1 Acute Myeloid Leukemia ClinicalTrials.gov
    Cretostimogene Grenadenorepvec DRUG Phase PHASE2 High-Risk Non-Muscle-Invasive Bladder Cancer ClinicalTrials.gov
    Questionnaire Administration OTHER Phase PHASE2 Acute Myeloid Leukemia ClinicalTrials.gov
    Multigated Acquisition Scan PROCEDURE Phase PHASE2 Acute Myeloid Leukemia ClinicalTrials.gov
    Leukapheresis PROCEDURE Phase PHASE2 Acute Myeloid Leukemia ClinicalTrials.gov
    Hydroxyurea DRUG Phase PHASE2 Acute Myeloid Leukemia ClinicalTrials.gov
    Echocardiography Test PROCEDURE Phase PHASE2 Acute Myeloid Leukemia ClinicalTrials.gov
    Bone Marrow Biopsy PROCEDURE Phase PHASE2 Acute Myeloid Leukemia ClinicalTrials.gov
    Bone Marrow Aspiration PROCEDURE Phase PHASE2 Acute Myeloid Leukemia ClinicalTrials.gov
    Biospecimen Collection PROCEDURE Phase PHASE2 Acute Myeloid Leukemia ClinicalTrials.gov
    imatinib mesylate DRUG Phase PHASE1 Gastrointestinal Stromal Tumor (GIST) ClinicalTrials.gov
    Granulocyte colony-stimulating factor BIOLOGICAL Phase PHASE1 AML ClinicalTrials.gov
    Gilteritinib DRUG Phase PHASE1 AML ClinicalTrials.gov
    Idarubicin DRUG Phase PHASE1 AML ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing
    • Regulatory Approval: Not available
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Kura Oncology Inc
    • CIK: 0001422143
    • Ticker Symbol: KURA
    • Period End Date: 2025-10-24
    • Document Type: 8-K

Search

News categories